A Reinforcement Learning-driven Translation Model for Search-Oriented Conversational Systems

Search-oriented conversational systems rely on information needs expressed in natural language (NL). We focus here on the understanding of NL expressions for building keyword-based queries. We propose a reinforcement-learning-driven translation model framework able to 1) learn the translation from NL expressions to queries in a supervised way, and, 2) to overcome the lack of large-scale dataset by framing the translation model as a word selection approach and injecting relevance feedback in the learning process. Experiments are carried out on two TREC datasets and outline the effectiveness of our approach.Comment: This is the author's pre-print version of the work. It is posted here for your personal use, not for redistribution. Please cite the definitive version which will be published in Proceedings of the 2018 EMNLP Workshop SCAI: The 2nd International Workshop on Search-Oriented Conversational AI - ISBN: 978-1-948087-75-

Multimodal Representations for Teacher-Guided Compositional Visual Reasoning

Neural Module Networks (NMN) are a compelling method for visual question answering, enabling the translation of a question into a program consisting of a series of reasoning sub-tasks that are sequentially executed on the image to produce an answer. NMNs provide enhanced explainability compared to integrated models, allowing for a better understanding of the underlying reasoning process. To improve the effectiveness of NMNs we propose to exploit features obtained by a large-scale cross-modal encoder. Also, the current training approach of NMNs relies on the propagation of module outputs to subsequent modules, leading to the accumulation of prediction errors and the generation of false answers. To mitigate this, we introduce an NMN learning strategy involving scheduled teacher guidance. Initially, the model is fully guided by the ground-truth intermediate outputs, but gradually transitions to an autonomous behavior as training progresses. This reduces error accumulation, thus improving training efficiency and final performance.We demonstrate that by incorporating cross-modal features and employing more effective training techniques for NMN, we achieve a favorable balance between performance and transparency in the reasoning process

Curriculum Learning for Compositional Visual Reasoning

Visual Question Answering (VQA) is a complex task requiring large datasets and expensive training. Neural Module Networks (NMN) first translate the question to a reasoning path, then follow that path to analyze the image and provide an answer. We propose an NMN method that relies on predefined cross-modal embeddings to ``warm start'' learning on the GQA dataset, then focus on Curriculum Learning (CL) as a way to improve training and make a better use of the data. Several difficulty criteria are employed for defining CL methods. We show that by an appropriate selection of the CL method the cost of training and the amount of training data can be greatly reduced, with a limited impact on the final VQA accuracy. Furthermore, we introduce intermediate losses during training and find that this allows to simplify the CL strategy

Investigation of Agricultural Waste as Economical and Effective Bio-Inhibitors for Inhibiting Scaling in Natural Hard Water

In this study, agricultural waste was utilized as new bio-inhibitors to prevent scale formation in hard waters. Aqueous extracts of strawberry and tomato leaves were utilized for reducing the scale deposits formed on metallic surfaces by Bounouara ground hard water, which supplies Constantine city in Algeria. Anti-scaling properties were evaluated by chronoamperometry and impedancemetry techniques. The effect of temperature and concentration on the efficiency of the bio-inhibitors was assessed. The results showed that the anti-scaling effect of strawberry leaf extracts started at the very low concentration of 1 ppm, with 31% efficiency, reaching complete scaling inhibition at 15 ppm (20ºC), whereas the inhibitory effect of tomato leaf extracts was noticed at 2.5 ppm, with 36% efficiency, and total inhibition at 20 ppm (20ºC). The efficiency of strawberry and tomato leaf extracts at 40∘C was also confirmed, although total inhibition was attained at a higher concentration. Keywords: hard water, agricultural waste, strawberry leaves, tomato leaves, bioinhibitors, scaling inhibitio

Leucémie à plasmocytes : A propos de 5 observations cliniques: Plasma cell leukemia: report of 5 cases report

Plasma cell leukemia is a malignant plasma cell proliferation in bone marrow and peripheral blood. It is the most agressive form of plasma cell malignancies. It occurs in two forms: primary and secondary plasma cell leukemia. Plasma cell leukemia is defined by the presence of more than 2Giga/l peripheral blood plasma cells or plasmocytosis more than 20% of leukocyte count. In this context, we report 5 observations of plasma cell leukemia (1 case of primary plasma cell leukemia and 4 cases of secondary plasma cell leukemia) encountered during 9 years in Farhat Hached Hospital in Sousse-Tunisia. Through these observations, we describe clinical, paraclinical, prognostic and therapeutic characteristics of this pathology. La leucémie à plasmocytes est une prolifération maligne de cellules plasmocytaires dans la moelle osseuse et le sang périphérique. Elle représente la forme la plus agressive des néoplasies plasmocytaires. Elle se présente sous deux formes : une forme primitive et une forme secondaire compliquant un myélome multiple. Elle est définie par une plasmocytose sanguine supérieure à 2 Giga/l ou un taux de plasmocytes supérieur à 20% des leucocytes. Dans ce contexte, nous rapportons 5 observations de leucémie à plasmocytes (1 cas de leucémie à plasmocytes primitive et 4 cas de leucémie à plasmocytes secondaire) survenus en 9 ans à l’hôpital Farhat Hached de Sousse (Tunisie). A travers ces observations, nous décrivons les caractéristiques cliniques, paracliniques, pronostiques et thérapeutiques de cette pathologie. &nbsp

Catamenial pneumothorax revealing diaphragmatic endometriosis: a case report and revue of literature

Catamenial pneumothorax (CP) is a rare entity of spontaneous, recurring pneumothorax in women. We aim to discuss the etiology, clinical course, and surgical treatment of a 42-year-old woman with CP. This patient had a right-sided spontaneous pneumothoraces occurred one week after menses. She had under-gone video-assisted thoracoscopic surgery (VATS) because of a persistent air leak under chest tube. VATS revealed multiple diaphragmatic fenestrations with an upper right nodule. Defects were removed and a large part of the diaphragm was resected. Pleural abrasion was then performed over the diaphragm. Diaphragmatic endometriosis was confirmed by microscopic examination. Medical treatment with GnRH agonists was prescribed, and after recovery, the patient has been symptoms free for 20 months.Keywords: Catamenial pneumothorax, endometriosis, surgical treatmen

Lung Adenocarcinoma with Gingival Metastasis

Gingival metastasis of lung cancer is uncommon. We report the case of an 82-year-old male smoker admitted to the pulmonology department with right pleural effusion. A chest computed tomography (CT) scan showed an invasive right hilar tumour, adherent to the superior vena cava, pulmonary artery, main right bronchus, mediastinal pleura and pericardium with lymphangitic carcinomatosis of the right lung. Pleural biopsy revealed pleural metastasis of pulmonary adenocarcinoma, its primary lung origin being confirmed by immunohistochemistry. One month later, the patient developed an ulcerated polypoid gingival mass. Biopsy of this lesion showed a poorly differentiated carcinoma compatible with metastasis from the lung adenocarcinoma. The patient underwent irradiation of the gingival mass at a dose of 30 Gray, but his condition worsened rapidly and he was not fit for chemotherapy. He received palliative treatment and died 2 months after diagnosis of his metastatic lung cancer

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Erythema Nodosum Revealing Metastatic Lung Cancer

Erythema nodosum (EN) is an inflammatory condition of the subcutaneous fat and has been reported in patients with haematological malignancies (lymphomas) or solid tumours. Lung cancer is the most common cause of paraneoplastic syndrome. We report a case of EN occurring as a paraneoplastic disease.A 48-year-old Tunisian woman, a non-smoker with no relevant medical history, presented with painful, erythematous, firm nodules on her legs with ankle swelling. The patient did not report any other symptoms. There were no abnormalities on examination except for moderate fever. An extensive infectious and immunological investigation was negative. Antistreptolysin antibodies were undetectable. Chest radiography showed a focal opacity in the right lung and a CT scan revealed a mass in the lower right pulmonary lobe with hilar and mediastinal lymphadenopathies, a nodule in the right adrenal gland, condensation in the iliac bone and multiple bilateral nodular cerebral expansive processes. Bronchial biopsies revealed a primitive and moderately differentiated adenocarcinoma. No argument for tuberculosis or sarcoidosis was foun